KidneyIntelX for CKD Etiology
Disease sub-typing and causation in broad CKD population
ResearchDevelopment
Key Facts
Indication
Disease sub-typing and causation in broad CKD population
Phase
Research
Status
Development
Company
About Renalytix
Renalytix plc is a global diagnostics company with a mission to improve kidney health through AI-enabled risk prediction. Its key achievement is the FDA authorization and subsequent Medicare coverage determination for its KidneyIntelX.dkd prognostic test for diabetic kidney disease. The company's strategy is to commercialize this test and expand its platform to other kidney conditions, leveraging partnerships to drive adoption and integrate its solutions into standard care pathways.
View full company profile